Fawzi Benzaghou, M.D.

Chief Medical Officer

Fawzi Benzaghou is a seasoned oncology leader with deep industry and regulatory experience spanning all stages of global drug development. Most recently, Fawzi served as Senior Vice President, Global Head of Oncology R&D at Ipsen. During his tenure there, Fawzi led the development of several currently approved treatments, including Cabometyx^® (cabozantinib) across several solid tumor types and Onivyde^® in pancreatic cancer, and participated in numerous IND submissions. At Ipsen, he held multiple senior global roles including Vice President of Late-Stage Oncology, Vice President of Innovation Oncology and Global Asset Lead for various oncology products. Prior to his roles at Ipsen, Fawzi worked as Head of Development at a European-based clinical-stage biotech focused on oncology therapies, notably leading the successful European approval of a prostate cancer therapy.

Fawzi is a board-certified pediatric surgeon and a graduate from Paris University, where he practiced for several years, including at Necker Children’s Hospital, a top European medical research center, obtaining several certificates in oncology and clinical research. He also holds a master’s degree in strategy and management in health industries from ESSEC Business School and is a graduate of Harvard Business School. Fawzi is a member of several scientific societies including the American Society of Clinical Oncology and the European Society for Medical Oncology, and is a co-author of several peer-reviewed publications.